Decoy Therapeutics (NASDAQ:DCOY) Posts Quarterly Earnings Results

Decoy Therapeutics (NASDAQ:DCOY) announced its quarterly earnings data on Friday. The company reported ($4.18) EPS for the quarter, FiscalAI reports.

Decoy Therapeutics Trading Down 0.3%

Shares of NASDAQ:DCOY traded down $0.02 during trading on Friday, reaching $5.72. The stock had a trading volume of 6,747 shares, compared to its average volume of 138,839. The firm’s fifty day moving average is $6.73. The firm has a market cap of $3.03 million, a PE ratio of -0.01 and a beta of 0.38. Decoy Therapeutics has a fifty-two week low of $5.15 and a fifty-two week high of $415.80.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Decoy Therapeutics in a research report on Friday, January 23rd. They set a “buy” rating and a $30.00 target price for the company. Wall Street Zen upgraded shares of Decoy Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, Weiss Ratings upgraded shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $30.00.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.